FHAM
TEVA icon

Folger Hill Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Folger Hill Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-300,000
Closed -$5.13M – 160
2018
Q1 		$5.13M Buy
300,000
+230,000
+329% +$4.49M 0.34% 92
2017
Q4 		$1.33M Buy
+70,000
New +$1.05M 0.13% 144

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Folger Hill Asset Management's TEVA Position: Q2 2018 in Review

Folger Hill Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2018, closing a stake of 300,000 shares — an estimated $5.13M sold.

Folger Hill Asset Management first reported a position in TEVA in Q4 2017 and held it in 2 quarters. The position peaked at $5.13M in Q1 2018. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2018.

  • Folger Hill Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Folger Hill Asset Management sold 300,000 Teva Pharmaceuticals shares in Q2 2018, an estimated $5.13M.
  • Folger Hill Asset Management first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Folger Hill Asset Management's Teva Pharmaceuticals position peaked at $5.13M in Q1 2018.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2018.

Based on Folger Hill Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.